Autoantibodies and overlap syndromes in autoimmune rheumatic disease

Journal of Clinical Pathology

Volumn 54, Issue 5, 2001, Pages 340-347

  Jury, E C ^a   D'Cruz, D ^b   Morrow, W J W ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Autoantibodies; Autoimmune rheumatic disease; Overlap syndromes

Indexed keywords

AUTOANTIBODY; TRANSFER RNA;

ANTIBODY DETECTION; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; COMORBIDITY; DERMATOMYOSITIS; DISEASE CLASSIFICATION; HUMAN; MIXED CONNECTIVE TISSUE DISEASE; POLYMYOSITIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RHEUMATIC DISEASE; SCLERODERMA; SERODIAGNOSIS; SJOEGREN SYNDROME; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSFER RNA SYNTHASE SYNDROME;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; PROGNOSIS; RHEUMATIC DISEASES; SYNDROME;

EID: 0035020855     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.54.5.340     Document Type: Review

References (99)

1. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-5.
2. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1987; 31:315-24.
3. Johnson PJ, McFarlane IG, Meeting report of the international autoimmune hepatitis group. Hepatology 1993;18: 998-1005.
4. Cervera R, Khamashta MA, Hughes GVR. Overlap syndromes. Ann Rheum Dis 1990;49:947-8.
5. Maddison PJ. Mixed connective tissue disease, overlap syndromes and eosinophilic fasciitis. Ann Rheum Dis 1991;50: 887-93.
6. Manns MP. Recent developments in autoimmune liver diseases. J Gastroenterol Hepatol 1997;12(suppl):S256-71.
7. Mimori T. Structures targeted by the immune system in myositis. Curr Opin Rheumatol 1996;8:521-7.
8. Mimori T. Autoantibodies in connective tissue diseases: clinical significance and analysis of target autoantigens. Intern Med 1999;38:523-32.
9. Fine RM. Overlap syndromes. Int J Dermatol 1991;30:479-80.
10. Isenberg DA, Black C. Naming names! Comment on the article by Smolen and Steiner. Arthritis Rheum 1999;42: 191-6.
11. Brand CA, Rowley MJ, Tait BD, et al. Coexistent rheumatoid arthritis and systemic lupus erythematosus: clinical, serological and phenotypic features. Ann Rheum Dis 1992;51:173-6.
12. Horiki T, Moriuchi J, Takaya M, et al. The coexistence of systemic sclerosis and rheumatoid arthritis in five patients: clinical and immunogenetic features suggest a distinct entity. Arthritis Rheum 1996;39:152-6.
13. Nimelstein SH, Brody ST, McShane D, et al. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 1980;59:239-48.
14. LeRoy EC, Maricq HR, Kalaleh MB. Undifferentiated connective tissue syndromes. Arthritis Rheum 1980;23:341-3.
15. Black C, Isenberg D. Mixed connective tissue disease-goodbye to all that, Br J Rheumatol 1993;32:348-9.
16. Williams HJ, Alarcon GS, Neuner R, et al. Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases. J Rheumatol 1998;25:261-8.
17. Alarcon GS. Unclassified or undifferentiated connective tissue disease. Baillieres Best Practice and Research in Clinical Rheumatology 2000;14;125-37.
18. Sharp GC, Hoffman DO. Clinical, immunologic and immunogenetic evidence that mixed connective tissue disease is a distinct entity: comment on the article by Smolen and Steiner. Arthritis Rheum 1999;42:190-1.
19. Van den Hoogen FHJ, van de Putte LBA. Is mixed connective tissue disease a myth? In: Isenberg DA, Tucker LB, eds. Controversies in rheumatology. London: Dunitz, 1997:87-95.
20. Maddison PJ. Mixed connective tissue disease: overlap syndromes. Baillieres Best Practice and Research in Clinical Rheumatology 2000;14:111-24.
21. Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be? Athritis Rheum 1998;41:768-77.
22. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972;52:148-59.
23. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;52:148-51.
24. Alarcon-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue diseases. In: Kasukawa R, Sharp GC, eds. Mixed connective tissue diseases and anti-nuclear antibodies. Amsterdam: Elsevier, 1987:33-40.
25. Kasukawa R, Tojo T, Miyawaki S, et al. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. Mixed connective tissue diseases and anti-nuclear antibodies. Amsterdam: Elsevier, 1987:41-7.
26. Steiner G, Skriner K, Smolen JS. Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Int Arch Allergy Immunol 1996;111:314-19.
27. Hoet RM, Koornneef DJ, De Rooij LB, et al. Changes in anti-U1 RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome. Arthritis Rheum 1992;35:1202-9.
28. Komatireddy GR, Wang GS, Sharp GC, et al. Antiphospholipid antibodies among anti-U1-70kDa autoantibody positive patients with mixed connective tissue disease. J Rheumatol 1997;24:319-22.
29. Hassfeld W, Steiner G, Studnicka A, et al. Autoimmune response to the spliceosome: an immunologic link between rheumatoid arthritis, mixed connective tissue disease and systemic lupus erythematosus. Arthritis Rheum 1995;38: 777-85.
30. Klein Gunnewiek JMT, Van De Putte LBA, Van Venrooij WJ. The U1 snRNP complex: an autoantigen in connective tissue diseases. An update. Clin Exp Rheumatol 1997;15: 549-60.
31. Margaux J, Hayem G, Palazzo E, et al. Clinical usefulness of autoantibodies to U1snRNP proteins in mixed connective tissue disease and systemic lupus erythematosus. Rev Rhum Engl Ed 1998;65:378-86.
32. Hoet RMA, Pieffers M, Stassen MHW, et al. The importance of the light chain for the epitope specificity of human anti-U1 small nuclear RNA autoantibodies present in systemic lupus erythematosus patients. J Immunol 1999; 163:3304-12.
33. Burdt MA, Hoffman RW, Deutscher SL, et al. Long term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999;42: 899-909.
34. Steiner G, Skriner K, Hassfeld W, et al. Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins - a link between RA, SLE and MCTD. Mol Biol Rep 1996;23:167-71.
35. Barakat S, Briand JP, Abuaf N, et al. Mapping of epitopes on U1 sn RNP polypeptide A with synthetic peptides and autoimmune sera. Clin Exp Immunol 1991;86:71-8.
36. Hassan AB, Ronnelid J, Gunnarsson I, et al. Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease. J Autoimmun 1998;11:503-8.
37. Hoffman RW, Sharp GC, Deutscher SL. Analysis of anti-U1 RNA antibodies in patients with connective tissue disease: association with HLA and clinical manifestations of disease. Arthritis Rheum 1995;38:1837-44.
38. Mimori T. Structures targeted by the immune system in myositis. Curr Opin Rheumatol 1996;8:521-27.
39. Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994;20:857-80.
40. Targoff IN. Autoantibodies in polymyositis. Rheum Dis Clin North Am 1992;18:455-82.
41. Morrow WJW, Nelson JL, Watts RA, et al. Sjögren's syndrome. In: Autoimmune rheumatic disease, 2nd ed. Oxford: Oxford University Press, 1999:147-241.
42. Marguerie C, Bunn CC, Copier J, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase. Q J Med 1990;77:1019-38.
43. Alarcon-Segovia D. Mixed connective tissue disease and overlap syndromes. Clin Dermatol 1994;12:309-16.
44. Miller FW. Myositis specific antibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993; 270:1846-9.
45. O'Neill TW, Maddison PJ. Rheumatoid arthritis associated with myositis and anti-Jo-1 antibody. J Rheumatol 1993;20: 141-3.
46. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
47. Plotz PH, Autoantibodies are anti-idiotype antibodies to antiviral antibodies. Lancet 1983;ii:824-6.
48. Garton MJ, Isenberg DA. Clinical features of lupus myositis versus idiopathic myositis: a review of 30 cases. Br J Rheumatol 1997;36:1067-74.
49. Ioannou Y, Sultan S, Isenberg DA. Myositis overlap syndromes. Curr Opin Rheumatol 1999;11:468-74.
50. Bennett RM. Scleroderma overlap syndromes. Rheumatic Dis Clin North Am 1990;16:185-98.
51. Jablonska S, Chorzelski TP, Blaszezyk M, et al. Scleroderma/polymyositis overlap syndromes and their immunologic markers. Clin Dermatol 1993;10:443-56.
52. Tuffanelli DL, Winkelmann RK. Systemic scleroderma. A clinical study of 727 cases. Arch Dermatol 1961;84:359-71.
53. Reichlin M, Maddison P, Targoff I, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984;4:40-4.
54. Bluthner M, Bautz EKF, Bautz FA. Mapping of epitopes recognised by PM/Scl autoantibodies with gene-fragment phage display libraries. J Immunol Methods 1996;198:187-98.
55. Alderuccio F, Chan EKL, Tan EM. Molecular characterization of an autoantigen of PM/Scl in the polymyositis/scleroderma overlap syndrome. J Exp Med 1991;173:941-52.
56. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al. Clinical, serologic and immunogenetic features in Polish patiants with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:1257-66.
57. Yamanishi Y, Maeda H, Katayama S, et al. Scleroderma-polymyositis overlap syndrome associated with anti-Ku antibody and rimmed vacuole formation. J Rheumatol 1996;23:1991-4.
58. Mimori T, Akizuki M, Yamagata H, et al. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest 1981;68: 611-20.
59. Bunn CC, Black CM. Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 1999;117:207-8.
60. Akiyama Y, Tanaka M, Takeishi M, et al. Clinical, serological and genetic study in patients with CREST syndrome. Intern Med 2000;39:451-6.
61. Horiki T, Moriuchi J, Takaya M, et al. The coexistence of systemic sclerosis and rheumatoid arthritis in five patients: clinical and immunogenic features suggest a distinct entity. Arthritis Rheum 1996;39:152-6.
62. Moutsopoulos HM, Manoussakis MN. Lumping or splitting autoimmune rheumatic disorders? Lessons from Sjogren's syndrome. Br J Rheumatol 1998;37:1263-4.
63. Von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-58.
64. Elagib KE, Borretzen M, Jonsson R, et al. Rheumatoid factors in primary Sjogren's syndrome (pSS) use diverse VH region genes, the majority of which show no evidence of somatic hypermutation. Clin Exp Immunol 1999;117:388-94.
65. Elagib KEE, Tengner PIA, Levi M, et al. Immunoglobulin variable genes and epitope recognition of human monoclonal anti-Ro 52-kd in primary Sjogrens syndrome. Arthritis Rheum 1999;42:2471-81.
66. Scofield RH, Farris AD, Horsfall AC, et al. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis Rheum 1999;42:199-209.
67. Kelekar A, Saitta MR, Keene JD. Molecular composition of Ro small ribonucleoprotein complexes in human cells: intracellular localisation of the 60- and 52kD proteins. J Clin Invest 1994;93:1637-44.
68. Ricchiuti V, Briand JP, Meyer O, et al. Epitope mapping with synthetic peptides of 52 kDa SSA/Ro protein reveals heterogeneous antibody profiles in human autoimmune sera. Clin Exp Immunol 1994;95:397-407.
69. Feist E, Kuckelkorn U, Dorner T, et al. Autoantibodies in primary Sjogren's syndrome are directed against proteasomal subunits of the α and β type. Arthritis Rheum 1999;42: 697-702.
70. Praprotnik S, Bozic B, Kveder T, et al. Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lupus erythematosus and Sjogren's syndrome: a prospective study. Clin Exp Rheumatol 1999;17:63-8.
71. Buyon JP. Neonatal lupus syndromes. Curr Opin Rheumatol 1994;6:523-9.
72. Topfer F, Gordon T, McCluskey J. Intra- and intermolecular spreading of autoimmunity involving the nuclear self antigens La (SS-B) and Ro (SS-A). Proc Natl Acad Sci USA 1995;92:875-79.
73. Venables PJW, Polymyositis-associated overlap syndromes. Br J Rheumatol 1996;35:305-6.
74. Tominaga M, Mitita K, Nakamura H, et al. Expression of metalloproteinase-2 (gelatinase A) in labial salivary glands of patients with Sjogren's syndrome with HTLV-1 infection. Clin Exp Rheumatol 1999;17:463-6.
75. Hida A, Kawabe Y, Kawakami A, et al. HTLV-1 associated Sjogren's syndrome is aetiologically distinct from anticentromere antibodies positive Sjogren's syndrome. Ann Rheum Dis 1999;58:320-2.
76. Ramos-Casals M, Garcia-Carrasco M, Cervera R, et al. Sjogren's syndrome and hepatitis C virus. Clin Rheumatol 1999;18:93-100.
77. Aragona P, Magazzu G, Macchia G, et al. Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjogren's syndrome. J Rheumatol 1999;26:1306-11.
78. Wilson RW, Provost TT, Bias WB, et al. Sjogren's syndrome. Influence of multiple HLA-D region alloantigens on clinical and serologic expression. Arthritis Rheum 1984;27: 1245-53.
79. Harley JB, Reichlin M, Arnett FC, et al. Gene interaction at HLA-DQ enhances autoantibody production in primary Sjogren's syndrome. Science 1986;232:1145-7.
80. Hamasaki K, Mimura T, Kanda H, et al. Development of systemic lupus erythematosus in a rheumatoid arthritis patient with anti-ribosomal P protein antibody. Lupus 1997;6:734-6.
81. Kaplan MM. Primary biliary cirrhosis, N Engl J Med 1987; 316:521-8.
82. Strassburg CP, Jaeckel E, Manns MP, Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:595-601.
83. Akimoto S, Ishikawa O, Takagi H, et al. Immunological features of patients with primary biliary cirrhosis (PBC) overlapping systemic sclerosis: a comparison with patients with PBC alone. J Gastroenterol Hepatol 1998;13:897-901.
84. Joplin RE, Neuberger JM. Immunopathology of primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:587-93.
85. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-5.
86. Powell FC, Schroeter AL, Dickson ER. Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med 1987;62:75-82.
87. Tubach F, Hatem G, Elias A, et al. Anticentromere antibodies in rheumatologic practice are not consistently associated with scleroderma. Rev Rhum Engl Ed 1997;64:362-7.
88. Akimoto S, Ishikawa O, Muro Y et al. Clinical and immunological characterisation of patients with systemic sclerosis overlapping primary biliary cirrhosis: a comparison with patients with systemic sclerosis alone. J Dermatol 1999;26: 18-22.
89. Fujimoto M, Sato S, Ihn Hironobu, et al. Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis: possible role of anti-E1α antibody as a serologic indicator for development of primary biliary cirrhosis. Arthritis Rheum 1995;38:985-9.
90. Mayo MJ, Jenkins RN, Combes B, et al. Association of clonally expanded T cells with the syndrome of primary biliary cirrhosis and limited scleroderma. Hepatology 1999;29: 1635-42.
91. Fujikura S, Davis P, Prindiville T, et al. Sjogren's syndrome and primary biliary cirrhosis: presence of autoantibodies to purified mitochondrial 2-OXO acid dehydrogenates. J Rheumatol 1990;17:1453-7.
92. Gohlke F, Lohse AW, Dienes HP, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996;24:699-705.
93. Klein R, Zanger UM, Berg T, et al. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes. Clin Exp Immunol 1999;118:290-7.
94. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-98.
95. Chazouilleres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28:296-301.
96. Lohse AW, Meyer zum Buschenfelde KH, Franz B, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-84.
97. Satoh T, Hirakata M, Yoshida T, et al. Systemic lupus erthyematosus associated with autoimmune hepatitis: two cases with novel autoantibodies to transfer RNA-related antigens. Clin Rheumatol 1997;16:305-9.
98. Reeves WH, Satoh M. Features of autoantigens. Mol Biol Rep 1996;23:217-26.
99. Fritzler MJ. Autoantibodies: diagnostic fingerprints and etiologic perplexities. Clin Invest Med 1997;20:50-6.